General Principles of Immunotherapy in Neurological Diseases-Reference-Cited by-同舟云学术

General Principles of Immunotherapy in Neurological Diseases

Published:2019 Issue: Volume: Page:387-421
ISSN:2627-535X
Container-title:Contemporary Clinical Neuroscience
language:
Short-container-title:

Author:

Rommer Paulus S.,Hecker Michael,Zrzavy Tobias,Boxberger Nina,Zettl Uwe K.

Publisher

Springer International Publishing

Link

https://link.springer.com/content/pdf/10.1007/978-3-030-19515-1_12

Reference221 articles.

1. Definition of Immunotherapy [Internet]. MedicineNet. [cited 2018 Oct 8]. Available from: https://www.medicinenet.com/script/main/art.asp?articlekey=7824

2. Gold R, Buttgereit F, Toyka KV. Mechanism of action of glucocorticosteroid hormones: possible implications for therapy of neuroimmunological disorders. J Neuroimmunol. 2001;117(1–2):1–8.

3. Drug Approval Package: Betaseron Interferon BETA-1B Subcutaneous (Generic Name) NDA # 103471 [Internet]. [cited 2018 Nov 12]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/103471s0000TOC.cfm

4. Rommer PS, Patejdl R, Zettl UK. Monoclonal antibodies in the treatment of neuroimmunological diseases. Curr Pharm Des. 2012;18(29):4498–507.

5. Rommer PS, Zettl UK. Managing the side effects of multiple sclerosis therapy: pharmacotherapy options for patients. Expert Opin Pharmacother. 2018;19(5):483–98.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The three pillars in treating antibody-mediated encephalitis;Wiener klinische Wochenschrift;2023-06-06

2. Literatur;Multiple Sklerose;2022

3. Prevention and management of adverse effects of disease modifying treatments in multiple sclerosis;Current Opinion in Neurology;2020-06